Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today